Loading clinical trials...

The Study of Pharmacokinetics of Levetiracetam in Patients Undergoing Intermittent Hemodialysis | Clinical Trials | Clareo Health

COMPLETED

The Study of Pharmacokinetics of Levetiracetam in Patients Undergoing Intermittent Hemodialysis

NCT04511676•Phramongkutklao College of Medicine and Hospital

View on ClinicalTrials.gov

Summary

Levetiracetam (LEV) is one of second-generation antiepileptic drugs that has been used to treat partial and generalized epilepsy. LEV is eliminated from the systemic circulation by renal excretion. Therefore, patients with renal impairment may experience a reduced drug excretion and increased adverse drug reactions. Moreover, patients with end-stage renal disease who need dialysis may experience low serum LEV concentration because of drug loss via dialysis. LEV loss via dialysis can cause low serum level of LEV that insufficient for seizure control. The present study was aimed to evaluate pharmacokinetics of LEV in patients undergoing 4 hour-intermittent hemodialysis (IHD). The results of the study may benefit to determine the appropriate LEV initial dose and supplemental dose for patients undergoing IHD.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Patients who were at least 18 years old.
•2. Patients who were diagnosed with seizure.
•3. Patients who were undergoing intermittent hemodialysis and were treated with intravenous Levetiracetam not less than 2 days

Exclusion Criteria

•1. Patients who were pregnant or lactating
•2. Patients who were treated with intravenous Levetiracetam more than once a day
•3. Patients who were undergoing sustained low efficiency dialysis (SLED)
•4. Patients who have intermittent dialysis duration less than 3 hours

Locations (1)

Pharmongkutklao Hospital

Ratchathewi, Bangkok, Thailand

Key Dates

Start Date

November 1, 2018

Primary Completion Date

October 10, 2019

Completion Date

October 10, 2019

Last Updated

August 13, 2020

Enrollment

ACTUAL participants

Conditions

Seizures

A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

NCT05077904

Stereotypical Prolonged Seizures

View study

RECRUITINGPHASE3

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

NCT05667142

Primary Generalized Tonic-Clonic Seizures

View study

RECRUITINGPHASE3

LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 13, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Study of Pharmacokinetics of Levetiracetam in Patients Undergoing Intermittent Hemodialysis

Inclusion Criteria

Exclusion Criteria

A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome

Longitudinal Study of Neurogenetic Disorders

SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures

Pharmacological Modulation of Brain Oscillations in Memory Processing